Erratum: Reversing the Warburg effect as a treatment for glioblastoma(Journal of Biological Chemistry (2013) 288 (9153–9164) DOI: 10.1074/jbc.M112.440354);Reversing the Warburg effect as a treatment for glioblastoma

Journal of Biological Chemistry

Volumn 288, Issue 13, 2013, Pages 9153-9164

  Poteet, Ethan ^a   Choudhury, Gourav Roy ^a   Winters, Ali ^a   Li, Wenjun ^a   Ryou, Myoung Gwi ^a   Liu, Ran ^a   Tang, Lin ^a   Ghorpade, Anuja ^a   Wen, Yi ^a   Yuan, Fang ^b   Keir, Stephen T ^c   Yan, Hai ^c   Bigner, Darell D ^c   Simpkins, James W ^a   Yang, Shao Hua ^a,b  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC COMPOUNDS; BIOCHEMISTRY; CELL CULTURE; CELL PROLIFERATION; ENZYME ACTIVITY;

ACETYL-COA CARBOXYLASE; AMP-ACTIVATED PROTEIN KINASE; CYCLIN EXPRESSION; GLIOBLASTOMA MULTIFORME; OXYGEN CONSUMPTION; PROOF OF CONCEPT; STRUCTURE ACTIVITY RELATIONSHIPS; TOLUIDINE BLUE O;

CELLS;

2 CHLOROPHENOTHIAZINE; ACETYL COENZYME A CARBOXYLASE; CYCLINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LACTIC ACID; METHYLENE BLUE; PHENOTHIAZINE DERIVATIVE; PROMETHAZINE; TEMOZOLOMIDE; TOLONIUM CHLORIDE; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOENERGY; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INACTIVATION; FEMALE; GLIOBLASTOMA; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TUMOR REGRESSION; WARBURG EFFECT;

EID: 84876004187     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.AAC118.005625     Document Type: Erratum

References (51)

1. Stupp, R., Dietrich, P. Y., Ostermann Kraljevic, S., Pica, A., Maillard, I., Maeder, P., Meuli, R., Janzer, R., Pizzolato, G., Miralbell, R., Porchet, F., Regli, L., de Tribolet, N., Mirimanoff, R. O., and Leyvraz, S. (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. 20, 1375-1382
2. Oertel, J., von Buttlar, E., Schroeder, H. W., and Gaab, M. R. (2005) Prognosis of gliomas in the 1970s and today. Neurosurg. Focus 18, e12
3. Lacroix, M., Abi-Said, D., Fourney, D. R., Gokaslan, Z. L., Shi, W., De-Monte, F., Lang, F. F., McCutcheon, I. E., Hassenbusch, S. J., Holland, E., Hess, K., Michael, C., Miller, D., and Sawaya, R. (2001) A multivariate analysis of 416 patients with glioblastoma multiforme. Prognosis, extent of resection, and survival. J. Neurosurg. 95, 190-198
4. Chamberlain, M. C., Glantz, M. J., Chalmers, L., Van Horn, A., and Sloan, A. E. (2007) Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J. Neurooncol 82, 81-83
5. Birol Sarica, F., Tufan, K., Cekinmez, M., Sen, O., Cem Onal, H., Mertsoylu, H., Topkan, E., Pehlivan, B., Erdogan, B., and Nur Altinors, M. (2010) Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme. Multivariate analysis and other prognostic factors. J. Neurosurg. Sci. 54, 7-19
6. Nieder, C., Adam, M., and Grosu, A. L. (2006) Combined modality treatment of glioblastoma multiforme. The role of temozolomide. Rev. Recent Clin. Trials 1, 43-51
7. Warburg, O. (1956) On the origin of cancer cells. Science 123, 309-314
8. Koppenol, W. H., Bounds, P. L., and Dang, C. V. (2011) Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 11, 325-337
9. Vander Heiden, M. G., Cantley, L. C., and Thompson, C. B. (2009) Understanding the Warburg effect. The metabolic requirements of cell proliferation. Science 324, 1029-1033
10. Ohlow, M. J., and Moosmann, B. (2011) Phenothiazine: the seven lives of pharmacology's first lead structure. Drug Discov, Today 16, 119-131
11. Rojas, J. C., Bruchey, A. K., and Gonzalez-Lima, F. (2012) Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog. Neurobiol. 96, 32-45
12. Wen, Y., Li, W., Poteet, E. C., Xie, L., Tan, C., Yan, L. J., Ju, X., Liu, R., Qian, H., Marvin, M. A., Goldberg, M. S., She, H., Mao, Z., Simpkins, J. W., and Yang, S. H. (2011) Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J. Biol. Chem. 286, 16504-16515
13. Atamna, H., Nguyen, A., Schultz, C., Boyle, K., Newberry, J., Kato, H., and Ames, B. N. (2008) Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J. 22, 703-712
14. Callaway, N. L., Riha, P. D., Wrubel, K. M., McCollum, D., and Gonzalez-Lima, F. (2002) Methylene blue restores spatial memory retention impaired by an inhibitor of cytochrome oxidase in rats. Neurosci. Lett. 332, 83-86
15. Sontag, E. M., Lotz, G. P., Agrawal, N., Tran, A., Aron, R., Yang, G., Necula, M., Lau, A., Finkbeiner, S., Glabe, C., Marsh, J. L., Muchowski, P. J., and Thompson, L. M. (2012) Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models. J. Neurosci. 32, 11109-11119
16. Medina, D. X., Caccamo, A., and Oddo, S. (2011) Methylene blue reduces a β levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol. 21, 140-149
17. Weinstein, J., Scott, A., and Hunter, F. E., Jr. (1964) The Action of gramicidin D on isolated liver mitochondria. J. Biol. Chem. 239, 3031-3037
18. Fields, J., Gardner-Mercer, J., Borgmann, K., Clark, I., and Ghorpade, A. (2011) CCAAT/enhancer binding protein β expression is increased in the brain during HIV-1-infection and contributes to regulation of astrocyte tissue inhibitor of metalloproteinase-1. J. Neurochem. 118, 93-104
19. Cao, J., Schulte, J., Knight, A., Leslie, N. R., Zagozdzon, A., Bronson, R., Manevich, Y., Beeson, C., and Neumann, C. A. (2009) Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J. 28, 1505-1517
20. Friedman, H. S., Colvin, O. M., Skapek, S. X., Ludeman, S. M., Elion, G. B., Schold, S. C., Jr., Jacobsen, P. F., Muhlbaier, L. H., and Bigner, D. D. (1988) Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res. 48, 4189-4195
21. Gehan, E. A. (1965) A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52, 203-223
22. Jeon, S. M., Chandel, N. S., and Hay, N. (2012) AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485, 661-665
23. Diaz-Ruiz, R., Rigoulet, M., and Devin, A. (2011) The Warburg and Crabtree effects. On the origin of cancer cell energy metabolism and of yeast glucose repression. Biochim. Biophys. Acta 1807, 568-576
24. Schulz, T. J., Thierbach, R., Voigt, A., Drewes, G., Mietzner, B., Steinberg, P., Pfeiffer, A. F., and Ristow, M. (2006) Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth. Otto Warburg revisited. J. Biol. Chem. 281, 977-981
25. DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., and Thompson, C. B. (2008) The biology of cancer. Metabolic reprogramming fuels cell growth and proliferation. Cell metab. 7, 11-20
26. Jones, R. G., and Thompson, C. B. (2009) Tumor suppressors and cell metabolism. A recipe for cancer growth. Genes Dev. 23, 537-548
27. McCarty, M. F., and Whitaker, J. (2010) Manipulating tumor acidification as a cancer treatment strategy. Altern. Med. Rev. 15, 264-272
28. Pagano, M., Pepperkok, R., Verde, F., Ansorge, W., and Draetta, G. (1992) Cyclin A is required at two points in the human cell cycle. EMBO J. 11, 961-971
29. Lindqvist, A., Rodríguez-Bravo, V., and Medema, R. H. (2009) The decision to enter mitosis. Feedback and redundancy in the mitotic entry network. J. Cell Biol. 185, 193-202
30. Lauper, N., Beck, A. R., Cariou, S., Richman, L., Hofmann, K., Reith, W., Slingerland, J. M., and Amati, B. (1998) Cyclin E2. A novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle. Oncogene 17, 2637-2643
31. Carling, D. (2004) The AMP-activated protein kinase cascade. A unifying system for energy control. Trends Biochem. Sci. 29, 18-24
32. Bolster, D. R., Crozier, S. J., Kimball, S. R., and Jefferson, L. S. (2002) AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J. Biol. Chem. 277, 23977-23980
33. Imamura, K., Ogura, T., Kishimoto, A., Kaminishi, M., and Esumi, H. (2001) Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-β- Dribofuranoside, in a human hepatocellular carcinoma cell line. Biochem. Biophys. Res. Commun. 287, 562-567
34. Hawley, S. A., Boudeau, J., Reid, J. L., Mustard, K. J., Udd, L., Mäkelä, T. P., Alessi, D. R., and Hardie, D. G. (2003) Complexes between the LKB1 tumor suppressor, STRAD α/β, and MO25 α/β are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2, 28
35. Jensen, T. E., Rose, A. J., Jørgensen, S. B., Brandt, N., Schjerling, P., Wojtaszewski, J. F., and Richter, E. A. (2007) Possible CaMKK-dependent regulation of AMPK phosphorylation and glucose uptake at the onset of mild tetanic skeletal muscle contraction. Am. J. Physiol. Endocrinol. Metab. 292, E1308-E1317
36. Luo, Z., Zang, M., and Guo, W. (2010) AMPK as a metabolic tumor suppressor. Control of metabolism and cell growth. Future Oncol 6, 457-470
37. Rattan, R., Giri, S., Hartmann, L. C., and Shridhar, V. (2011) Metformin attenuates ovarian cancer cell growth in anAMPkinase-dispensable manner. J. Cell. Mol. Med. 15, 166-178
38. Xiang, X., Saha, A. K., Wen, R., Ruderman, N. B., and Luo, Z. (2004) AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem. Biophys. Res. Commun. 321, 161-167
39. Youn, S. H., Lee, J. S., Lee, M. S., Cha, E. Y., Thuong, P. T., Kim, J. R., and Chang, E. S. (2012) Anticancer properties of pomolic acid-induced AMPactivated protein kinase activation in MCF7 human breast cancer cells. Biol. Pharm. Bull 35, 105-110
40. Zhou, J., Huang, W., Tao, R., Ibaragi, S., Lan, F., Ido, Y., Wu, X., Alekseyev, Y. O., Lenburg, M. E., Hu, G. F., and Luo, Z. (2009) Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells. Oncogene 28, 1993-2002
41. Wu, N., Gu, C., Gu, H., Hu, H., Han, Y., and Li, Q. (2011) Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma 58, 482-490
42. Wang, W., Fan, J., Yang, X., Fürer-Galban, S., Lopez de Silanes, I., von Kobbe, C., Guo, J., Georas, S. N., Foufelle, F., Hardie, D. G., Carling, D., and Gorospe, M. (2002) AMP-activated kinase regulates cytoplasmic HuR. Mol. Cell. Biol. 22, 3425-3436
43. Wakil, S. J., Stoops, J. K., and Joshi, V. C. (1983) Fatty acid synthesis and its regulation. Annu. Rev. Biochem. 52, 537-579
44. Park, S. H., Gammon, S. R., Knippers, J. D., Paulsen, S. R., Rubink, D. S., and Winder, W. W. (2002) Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. J. Appl. Physiol. 92, 2475-2482
45. Chung, J., Kuo, C. J., Crabtree, G. R., and Blenis, J. (1992) Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70-kDa S6 protein kinases. Cell 69, 1227-1236
46. Price, D. J., Grove, J. R., Calvo, V., Avruch, J., and Bierer, B. E. (1992) Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 257, 973-977
47. Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., and Yonezawa, K. (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110, 177-189
48. Sarbassov, D. D., Guertin, D. A., Ali, S. M., and Sabatini, D. M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101
49. Zakikhani, M., Blouin, M. J., Piura, E., and Pollak, M. N. (2010) Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res. Treat 123, 271-279
50. Emerling, B. M., Weinberg, F., Snyder, C., Burgess, Z., Mutlu, G. M., Viollet, B., Budinger, G. R., and Chandel, N. S. (2009) Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ATP ratio. Free Radic. Biol. Med. 46, 1386-1391
51. Pepponi, R., Marra, G., Fuggetta, M. P., Falcinelli, S., Pagani, E., Bonmassar, E., Jiricny, J., and D'Atri, S. (2003) The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1- nitrosourea, and cisplatin. J. Pharmacol. Exp. Ther. 304, 661-668